Posts Archive

TRIMM-2 study A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment...

LocoMMotion Relapsed & Refractory Multiple Myeloma NCT04035226: A Study of Real-life Current Standards of Care in Patients With Relapsed...

CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...

A.R.R.O.W.2 NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and...

NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217...

DREAMM 3 Relapsed & Refractory Myeloma v NCT04162210: Phase 3 - Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone...

ABBV-383 (formerly TNB-383B) TNB-383B, a Bispecific Antibody Targeting BCMA BCMA x CD3 T-cell engaging bispecifc antibody RRMM...

DREAMM 5 Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With...

NCT03848845: Phase 1/2: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in...

(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...

CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma Study CC-93269-MM-001...

KarMMa-3 bb2121 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...

CANOVA TRIAL t(11;14)-positive Relapsed or Refractory Multiple Myeloma. A Study of Venetoclax and Dexamethasone Compared With...

NCT03617731: Phase 3 - Effect of Isatuximab to RVd Induction and Lenalidomide Maintenance in NDMM (GMMG HD7) German-speaking myeloma...

DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...

The APOLLO study EMN14/54767414MMY3013 Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed...